DOCSLIB.ORG

D. Combined Drug-Drug Interactions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Appendix D D. Combined Drug-Drug Interactions This list contains all drug-drug interactions (both critical and significant) in National Drug File V. 3.18. The interactions are cross-referenced by each interacting ingredient. ACEBUTOLOL CRITICAL INTERACTION WITH VERAPAMIL ACEBUTOLOL SIGNIFICANT INTERACTION WITH ACETOHEXAMIDE ACEBUTOLOL SIGNIFICANT INTERACTION WITH CHLORPROPAMIDE ACEBUTOLOL SIGNIFICANT INTERACTION WITH CLONIDINE ACEBUTOLOL SIGNIFICANT INTERACTION WITH EPINEPHRINE ACEBUTOLOL SIGNIFICANT INTERACTION WITH FELODIPINE ACEBUTOLOL SIGNIFICANT INTERACTION WITH GLIPIZIDE ACEBUTOLOL SIGNIFICANT INTERACTION WITH GLYBURIDE ACEBUTOLOL SIGNIFICANT INTERACTION WITH INDOMETHACIN ACEBUTOLOL SIGNIFICANT INTERACTION WITH INSULIN ACEBUTOLOL SIGNIFICANT INTERACTION WITH PIROXICAM ACEBUTOLOL SIGNIFICANT INTERACTION WITH SULINDAC ACEBUTOLOL SIGNIFICANT INTERACTION WITH TOLAZAMIDE ACEBUTOLOL SIGNIFICANT INTERACTION WITH TOLBUTAMIDE ACETAMINOPHEN SIGNIFICANT INTERACTION WITH SULFINPYRAZONE ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH ACEBUTOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH ATENOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH BETAXOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH BISOPROLOL FUMARATE ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH CARTEOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH LABETALOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH METOPROLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH NADOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH PENBUTOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH PINDOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH PROPRANOLOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH SOTALOL ACETOHEXAMIDE SIGNIFICANT INTERACTION WITH TIMOLOL ALFENTANIL SIGNIFICANT INTERACTION WITH ERYTHROMYCIN ALLOPURINOL CRITICAL INTERACTION WITH AZATHIOPRINE ALLOPURINOL CRITICAL INTERACTION WITH MERCAPTOPURINE ALPRAZOLAM SIGNIFICANT INTERACTION WITH CLOZAPINE April 1998 National Drug File V. 3.18 105 User Manual Appendix D ALPRAZOLAM SIGNIFICANT INTERACTION WITH RITONAVIR ALTEPLASE CRITICAL INTERACTION WITH NITROGLYCERIN ALUMINUM CARBONATE SIGNIFICANT INTERACTION WITH CIPROFLOXACIN ALUMINUM CARBONATE SIGNIFICANT INTERACTION WITH DOXYCYCLINE ALUMINUM CARBONATE SIGNIFICANT INTERACTION WITH ENOXACIN ALUMINUM CARBONATE SIGNIFICANT INTERACTION WITH LOMEFLOXACIN ALUMINUM CARBONATE SIGNIFICANT INTERACTION WITH TETRACYCLINE ALUMINUM HYDROXIDE SIGNIFICANT INTERACTION WITH CIPROFLOXACIN ALUMINUM HYDROXIDE SIGNIFICANT INTERACTION WITH DOXYCYCLINE ALUMINUM HYDROXIDE SIGNIFICANT INTERACTION WITH ENOXACIN ALUMINUM HYDROXIDE SIGNIFICANT INTERACTION WITH LOMEFLOXACIN ALUMINUM HYDROXIDE SIGNIFICANT INTERACTION WITH TETRACYCLINE ALUMINUM PHOSPHATE SIGNIFICANT INTERACTION WITH CIPROFLOXACIN ALUMINUM PHOSPHATE SIGNIFICANT INTERACTION WITH DOXYCYCLINE ALUMINUM PHOSPHATE SIGNIFICANT INTERACTION WITH ENOXACIN ALUMINUM PHOSPHATE SIGNIFICANT INTERACTION WITH LOMEFLOXACIN ALUMINUM PHOSPHATE SIGNIFICANT INTERACTION WITH TETRACYCLINE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH BETAMETHASONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH CORTICOTROPIN AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH CORTISONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH COSYNTROPIN AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH DESOXYCORTICOSTERONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH DEXAMETHASONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH FLUDROCORTISONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH HYDROCORTISONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH METHYLPREDNISOLONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH PARAMETHASONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH PREDNISOLONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH PREDNISONE AMBENONIUM CHLORIDE SIGNIFICANT INTERACTION WITH TRIAMCINOLONE AMIKACIN SIGNIFICANT INTERACTION WITH AMPICILLIN AMIKACIN SIGNIFICANT INTERACTION WITH ATRACURIUM AMIKACIN SIGNIFICANT INTERACTION WITH BUMETANIDE AMIKACIN SIGNIFICANT INTERACTION WITH CARBENICILLIN AMIKACIN SIGNIFICANT INTERACTION WITH ETHACRYNIC ACID AMIKACIN SIGNIFICANT INTERACTION WITH FUROSEMIDE AMIKACIN SIGNIFICANT INTERACTION WITH GALLAMINE TRIETHIODIDE AMIKACIN SIGNIFICANT INTERACTION WITH METOCURINE IODIDE 106 National Drug File V. 3.18 April 1998 User Manual Combined Drug Interactions AMIKACIN SIGNIFICANT INTERACTION WITH MEZLOCILLIN AMIKACIN SIGNIFICANT INTERACTION WITH PANCURONIUM AMIKACIN SIGNIFICANT INTERACTION WITH PIPERACILLIN AMIKACIN SIGNIFICANT INTERACTION WITH TICARCILLIN AMIKACIN SIGNIFICANT INTERACTION WITH TORSEMIDE AMIKACIN SIGNIFICANT INTERACTION WITH TUBOCURARINE AMIKACIN SIGNIFICANT INTERACTION WITH VANCOMYCIN AMIKACIN SIGNIFICANT INTERACTION WITH VECURONIUM AMILORIDE SIGNIFICANT INTERACTION WITH BENAZEPRIL AMILORIDE SIGNIFICANT INTERACTION WITH CAPTOPRIL AMILORIDE SIGNIFICANT INTERACTION WITH ENALAPRIL AMILORIDE SIGNIFICANT INTERACTION WITH FOSINOPRIL AMILORIDE SIGNIFICANT INTERACTION WITH LISINOPRIL AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM ACETATE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM BICARBONATE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM CHLORIDE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM CITRATE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM GLUCONATE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM IODIDE AMILORIDE SIGNIFICANT INTERACTION WITH POTASSIUM PHOSPHATE AMILORIDE SIGNIFICANT INTERACTION WITH QUINAPRIL AMILORIDE SIGNIFICANT INTERACTION WITH QUINIDINE AMILORIDE SIGNIFICANT INTERACTION WITH RAMIPRIL AMILORIDE SIGNIFICANT INTERACTION WITH TRANDOLAPRIL AMINOPHYLLINE CRITICAL INTERACTION WITH CIMETIDINE AMINOPHYLLINE CRITICAL INTERACTION WITH CIPROFLOXACIN AMINOPHYLLINE CRITICAL INTERACTION WITH CLARITHROMYCIN AMINOPHYLLINE CRITICAL INTERACTION WITH ENOXACIN AMINOPHYLLINE CRITICAL INTERACTION WITH ERYTHROMYCIN AMINOPHYLLINE CRITICAL INTERACTION WITH NORFLOXACIN AMINOPHYLLINE CRITICAL INTERACTION WITH OLEANDOMYCIN (AS TROLEANDOMYCIN) AMINOPHYLLINE SIGNIFICANT INTERACTION WITH FLUOXETINE AMINOPHYLLINE SIGNIFICANT INTERACTION WITH FLUVOXAMINE MALEATE AMINOPHYLLINE SIGNIFICANT INTERACTION WITH FOSPHENYTOIN SODIUM AMINOPHYLLINE SIGNIFICANT INTERACTION WITH PHENOBARBITAL AMINOPHYLLINE SIGNIFICANT INTERACTION WITH PHENYTOIN AMINOPHYLLINE SIGNIFICANT INTERACTION WITH RIFAMPIN AMIODARONE CRITICAL INTERACTION WITH ANISINDIONE April 1998 National Drug File V. 3.18 107 User Manual Appendix D AMIODARONE CRITICAL INTERACTION WITH CYCLOSPORINE AMIODARONE CRITICAL INTERACTION WITH DICUMAROL AMIODARONE CRITICAL INTERACTION WITH DIGITALIS AMIODARONE CRITICAL INTERACTION WITH FENTANYL AMIODARONE CRITICAL INTERACTION WITH PHENPROCOUMON AMIODARONE CRITICAL INTERACTION WITH QUINIDINE AMIODARONE CRITICAL INTERACTION WITH SPARFLOXACIN AMIODARONE CRITICAL INTERACTION WITH WARFARIN AMIODARONE SIGNIFICANT INTERACTION WITH RITONAVIR AMITRIPTYLINE CRITICAL INTERACTION WITH CLONIDINE AMITRIPTYLINE CRITICAL INTERACTION WITH ISOCARBOXAZID AMITRIPTYLINE CRITICAL INTERACTION WITH PARGYLINE AMITRIPTYLINE CRITICAL INTERACTION WITH PHENELZINE AMITRIPTYLINE CRITICAL INTERACTION WITH SELEGILINE AMITRIPTYLINE CRITICAL INTERACTION WITH TRANYLCYPROMINE AMITRIPTYLINE SIGNIFICANT INTERACTION WITH FLUOXETINE AMITRIPTYLINE SIGNIFICANT INTERACTION WITH FLUVOXAMINE MALEATE AMOBARBITAL CRITICAL INTERACTION WITH ANISINDIONE AMOBARBITAL CRITICAL INTERACTION WITH DICUMAROL AMOBARBITAL CRITICAL INTERACTION WITH PHENPROCOUMON AMOBARBITAL CRITICAL INTERACTION WITH WARFARIN AMOXAPINE CRITICAL INTERACTION WITH CLONIDINE AMOXAPINE CRITICAL INTERACTION WITH ISOCARBOXAZID AMOXAPINE CRITICAL INTERACTION WITH PARGYLINE AMOXAPINE CRITICAL INTERACTION WITH PHENELZINE AMOXAPINE CRITICAL INTERACTION WITH SELEGILINE AMOXAPINE CRITICAL INTERACTION WITH TRANYLCYPROMINE AMOXAPINE SIGNIFICANT INTERACTION WITH FLUOXETINE AMOXAPINE SIGNIFICANT INTERACTION WITH FLUVOXAMINE MALEATE AMPHETAMINE CRITICAL INTERACTION WITH ISOCARBOXAZID AMPHETAMINE CRITICAL INTERACTION WITH PARGYLINE AMPHETAMINE CRITICAL INTERACTION WITH PHENELZINE AMPHETAMINE CRITICAL INTERACTION WITH TRANYLCYPROMINE AMPICILLIN SIGNIFICANT INTERACTION WITH AMIKACIN AMPICILLIN SIGNIFICANT INTERACTION WITH GENTAMICIN AMPICILLIN SIGNIFICANT INTERACTION WITH NETILMICIN AMPICILLIN SIGNIFICANT INTERACTION WITH TOBRAMYCIN ANISINDIONE CRITICAL INTERACTION WITH AMIODARONE 108 National Drug File V. 3.18 April 1998 User Manual Combined Drug Interactions ANISINDIONE CRITICAL INTERACTION WITH AMOBARBITAL ANISINDIONE CRITICAL INTERACTION WITH ASPIRIN ANISINDIONE CRITICAL INTERACTION WITH BISMUTH SUBSALICYLATE ANISINDIONE CRITICAL INTERACTION WITH CARBAMAZEPINE ANISINDIONE CRITICAL INTERACTION WITH CHOLINE SALICYLATE ANISINDIONE CRITICAL INTERACTION WITH CIMETIDINE ANISINDIONE CRITICAL INTERACTION WITH CLOFIBRATE ANISINDIONE CRITICAL INTERACTION WITH DANAZOL ANISINDIONE CRITICAL INTERACTION WITH DISULFIRAM ANISINDIONE CRITICAL INTERACTION WITH FLUCONAZOLE ANISINDIONE CRITICAL INTERACTION WITH ITRACONAZOLE ANISINDIONE CRITICAL INTERACTION WITH KETOCONAZOLE ANISINDIONE CRITICAL INTERACTION WITH MAGNESIUM SALICYLATE ANISINDIONE CRITICAL INTERACTION WITH MEPHOBARBITAL ANISINDIONE CRITICAL INTERACTION WITH MEPHOBARBITAL ANISINDIONE CRITICAL INTERACTION WITH METHYL SALICYLATE ANISINDIONE CRITICAL INTERACTION WITH MICONAZOLE ANISINDIONE CRITICAL INTERACTION WITH OXYPHENBUTAZONE ANISINDIONE CRITICAL INTERACTION WITH PENTOBARBITAL ANISINDIONE CRITICAL INTERACTION WITH PHENOBARBITAL ANISINDIONE CRITICAL INTERACTION WITH PHENYLBUTAZONE ANISINDIONE CRITICAL INTERACTION WITH PRIMIDONE ANISINDIONE CRITICAL INTERACTION WITH RIFAMPIN ANISINDIONE CRITICAL INTERACTION WITH SALSALATE
Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
  • Allosteric Drug Transport Mechanism of Multidrug Transporter Acrb

    Allosteric Drug Transport Mechanism of Multidrug Transporter Acrb

    ARTICLE https://doi.org/10.1038/s41467-021-24151-3 OPEN Allosteric drug transport mechanism of multidrug transporter AcrB ✉ Heng-Keat Tam 1,3,4 , Wuen Ee Foong 1,4, Christine Oswald1,2, Andrea Herrmann1, Hui Zeng1 & ✉ Klaas M. Pos 1 Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump + 1234567890():,; contains the inner membrane H /drug antiporter AcrB comprising three functionally inter- dependent protomers, cycling consecutively through the loose (L), tight (T) and open (O) state during cooperative catalysis. Here, we present 13 X-ray structures of AcrB in inter- mediate states of the transport cycle. Structure-based mutational analysis combined with drug susceptibility assays indicate that drugs are guided through dedicated transport chan- nels toward the drug binding pockets. A co-structure obtained in the combined presence of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane domain. Thiol cross-link substrate protection assays indicate that this transmembrane domain-binding site can also accommodate oxacillin or novobiocin but not erythromycin or linezolid. AcrB-mediated drug transport is suggested to be allos- terically modulated in presence of multiple drugs. 1 Institute of Biochemistry, Goethe-University Frankfurt, Frankfurt am Main, Germany. 2 Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, UK. 3Present
  • Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B

    Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B

    TRANSMITTAL NO. 37 - FEDERAL UPPER LIMIT DRUG LIST NOVEMBER 20, 2001 The following list of multiple source drugs meets the criteria set forth in 42 CFR 447.332 and Section 1927(e) of the Social Security Act, as amended by OBRA 1993. Payment for multiple source drugs identified and listed below must not exceed, in the aggregate, payment levels determined by applying to each drug entity a reasonable dispensing fee (established by the State and specified in the State plan), plus an amount based on the limit per unit which CMS has determined to be equal to 150 percent applied to the lowest price listed (in package sizes of 100 units, unless otherwise noted) in any of the published compendia of cost information of drugs. The listing is based on data current as of April 2001 from First Data Bank (Blue Book), Medi- Span, and the Red Book. This list does not reference the commonly known brand names. However, the brand names are included in the electronic FUL listing provided to the state agencies. The FUL price list and electronic listing are available at http://www.cms.hhs.gov/Reimbursement/05_FederalUpperLimits.asp. In accordance with current policy, Federal financial participation will not be provided for any drug on the FUL listing for which the FDA has issued a notice of an opportunity for a hearing as a result of the Drug Efficacy Study and Implementation (DESI) program, and which has been found to be a less than effective or is identical, related or similar (IRS) to the DESI drug. The DESI drug is identified by the Food and Drug Administration or reported by the drug manufacturer for purposes of the Medicaid drug rebate program.
  • Anaesthetic Experience with Paediatric Interventional Cardiology

    Anaesthetic Experience with Paediatric Interventional Cardiology

    320 Occasional Survey Anaesthetic experience with paediatric inter- Shobha Malviya MD, Frederick A. Burrows MD FRCPC, Albert E. Johnston MD FRCPC, Lee N. Benson MD FRCPC ventional cardiology Anaesthetic and sedation techniques, complications and out- In recent years interventional cardiologic procedures have comes were reviewed in 176 children undergoing 184 interven- replaced thoracic and cardiac surgery in the treatment of tional cardiologic procedures. Techniques included sedation certain cardiac anomalies in children. Balloon dilatation only, and ketamine, inhalational or narcotic anaesthesia. is particularly effective in treating pulmonary valve Ketamine infusion was the technique most frequently used. stenosis and is also performed as a nonsurgical alternative Ketamine was associated with a higher incidence of respiratory for patients with aortic valve stenosis, recoaretation of the complications (P < 0.05) than the other techniques. The higher aorta and pulmonary artery stenosis. Insertion of an incidence of hypercarbia (15.6 per cent), which did not affect occlusion device is used to treat patent ductus arteriosus. outcome, may be attributable to the use of supplemental Procedures performed in the cardiac catheterisation sedatives. The incidence of upper airway obstruction (7.8 per suite require a darkened room, allow poor access to the cenO was similar to that of previous studies. Vascular compro- often critically ill patient and present the potential for mise resulted from the procedure in 33 patients, necessitating sudden devastating complications, including rupture of a surgical correction in 16. Cardiac perforation occurred in four cardiac chamber. In addition, interventional procedures cases, causing one death. Pulmonary valve stenosis was most require a steady haemodynamic state before oxygen amenable to balloon dilatation and aortic valve stenosis least saturation and pressures in the various cardiac chambers amenable.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Potassium Iodide (KI): Instructions for Children

    Potassium Iodide (KI): Instructions for Children

    Potassium Iodide (KI): Instructions for Children The thyroid gland in children is very sensitive to the effects of radioactive iodine. In the event of a nuclear emergency, it is important for adults to understand how to prepare the proper dosage of potassium iodide (KI) for young children. The following information will help you to give KI to your children properly. Children over 12 years to 18 years 2 tablets (whole or crushed) (130 mg) (who weigh at least 150 pounds) Children over 12 years to 18 years 1 tablet (whole or crushed) or 8 teaspoons (65 mg) (who weigh less than 150 pounds) Children over 3 years to 12 years 1 tablet (whole or crushed) or 8 teaspoons (65 mg) Children over 1 month to 3 years 4 teaspoons (32.5 mg) Babies at birth to 1 month 2 teaspoons (16.25 mg) Tablets can be crushed and mixed in many liquids. To take the tablet in liquid solution, use dosing directions under “Making a Potassium Iodide Liquid Mixture.” Take KI only as directed by public officials. Do not take more than 1 dose in 24 hours. More will not help you. Too much medicine may increase the chances of side effects. Making a Potassium Iodide Liquid Mixture 1. Put one 65 mg KI tablet into a small bowl and grind it into a fine powder using the back of a metal teaspoon against the inside of the bowl. The powder should not have any large pieces. 2. Add 4 teaspoons of water to the crushed KI powder in the bowl and mix until the KI powder is dissolved in the water.
  • Product Monograph Vecuronium Bromide For

    Product Monograph Vecuronium Bromide For

    PRODUCT MONOGRAPH PrVECURONIUM BROMIDE FOR INJECTION Non-depolarizing Skeletal Neuromuscular Blocking Agent Pharmaceutical Partners of Canada Inc. Date of Preparation: 45 Vogell Road, Suite 200 January 15, 2008 Richmond Hill, ON L4B 3P6 Control No.: 119276 PRODUCT MONOGRAPH PrVECURONIUM BROMIDE FOR INJECTION Non-depolarizing Skeletal Neuromuscular Blocking Agent THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS AND HAZARDS ACTIONS AND CLINICAL PHARMACOLOGY Vecuronium Bromide for Injection is a non-depolarizing neuromuscular blocking agent of intermediate duration possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited and neuromuscular block reversed by acetylcholinesterase inhibitors such as neostigmine. Vecuronium Bromide for Injection is about 1/3 more potent than pancuronium; the duration of neuromuscular blockade produced by Vecuronium Bromide for Injection is shorter than that of pancuronium at initially equipotent doses. The time to onset of paralysis decreases and the duration of maximum effect increases with increasing Vecuronium Bromide for Injection doses. The use of a peripheral nerve stimulator is of benefit in assessing the degree of muscular relaxation. The ED90 (dose required to produce 90% suppression of the muscle twitch response with balanced anesthesia) has averaged 0.057 mg/kg (0.049 to 0.062 mg/kg in various studies). An initial Vecuronium Bromide for Injection dose of 0.08 to 0.10 mg/kg generally produces first depression of twitch in approximately 1 minute, good or excellent intubation conditions within 2.5 to 3 minutes, and maximum neuromuscular blockade within 3 to 5 minutes of injection in Vecuronium Bromide for Injection, Product Monograph Page 2 of 28 most patients.
  • Determination of Iodate in Iodised Salt by Redox Titration

    Determination of Iodate in Iodised Salt by Redox Titration

    College of Science Determination of Iodate in Iodised Salt by Redox Titration Safety • 0.6 M potassium iodide solution (10 g solid KI made up to 100 mL with distilled water) • 0.5% starch indicator solution Lab coats, safety glasses and enclosed footwear must (see below for preparation) be worn at all times in the laboratory. • 250 mL volumetric flask Introduction • 50 mL pipette (or 20 and 10 mL pipettes) • 250 mL conical flasks New Zealand soil is low in iodine and hence New Zealand food is low in iodine. Until iodised salt was • 10 mL measuring cylinder commonly used (starting in 1924), a large proportion • burette and stand of school children were reported as being affected • distilled water by iodine deficiency – as high as 60% in Canterbury schools, and averaging 20 − 40% overall. In the worst cases this deficiency can lead to disorders such as Method goitre, and impaired physical and mental development. 1. Preparation of 0.002 mol L−1 sodium thiosulfate In earlier times salt was “iodised” by the addition of solution: Accurately weigh about 2.5 g of solid potassium iodide; however, nowadays iodine is more sodium thiosulfate (NaS2O3•5H2O) and dissolve in commonly added in the form of potassium iodate 100 mL of distilled water in a volumetric flask. (This gives a 0.1 mol L−1 solution). Then use a pipette to (KIO3). The Australia New Zealand Food Standards Code specifies that iodised salt must contain: “equivalent to transfer 10 mL of this solution to a 500 mL volumetric no less than 25 mg/kg of iodine; and no more than 65 flask and dilute by adding distilled water up to the mg/kg of iodine”.
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column

    Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column

    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
  • Sulfinpyrazone 100Mg and 200Mg Tablets (Sulfinpyrazone)

    Sulfinpyrazone 100Mg and 200Mg Tablets (Sulfinpyrazone)

    Prescribing information sulfinpyrazone 100mg and 200mg tablets (sulfinpyrazone) Presentation: Coated tablets agents, sulphonamides, penicillin, theophylline, phenytoin, non- indication: Chronic, including tophaceous gout; recurrent gouty steroidal antirheumatic drugs. arthritis; hyperuricaemia Pregnancy and lactation: Used with caution in pregnant women, Dosage and administration: Route of administration: Oral. Adults: weighing the potential risk against the possible benefits. It is not known 100-200mg daily increasing gradually (over the first two or three whether the active substance or its metabolite(s) pass into breast milk. weeks) to 600mg daily (rarely 800mg), and maintained until the For safety reasons mothers should refrain from taking the drug. serum urate level has fallen within the normal range. Maintenance Undesirable effects: Mild transient gastro-intestinal upsets, such dose may be as low as 200mg daily. Children: Paediatric usage as nausea, vomiting, diarrhea, gastro-intestinal bleeding and not established. ulcers, acute renal failure, salt and water retention, allergic skin contraindications: Acute attacks of gout. Gastric and duodenal reactions, leucopenia, thrombocytopenia, agranulocytosis, aplastic ulcer. Known hypersensitivity to sulfinpyrazone and other pyrazolone anaemia, hepatic dysfunction, jaundice and hepatitis. derivatives. Contra-indicated in patients with asthma, urticaria, or (Please refer to the Summary of Product Characteristics for acute rhinitis, severe parenchymal lesions of the liver or kidneys, detailed information) porphyria, blood dyscrasias, haemorrhagic diatheses overdose: Nausea, vomiting, abdominal pains, diarrhoea, Precautions and warnings: Used with caution in patients with hypotension, cardiac arrhythmias, hyperventilation, respiratory hyperuricaemia or gout, episodes of urolithiasis or renal colic, disorders, impairment of consciousness, coma, epileptic seizures, ensure adequate fluid intake and alkalinisation of the urine during oliguria or anuria, acute renal failure, renal colic.
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042

    Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042

    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.